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Balancing the Risks of Restenosis and Stent
Thrombosis in Bare-Metal Versus Drug-Eluting Stents
Results of a Decision Analytic Model
Pallav Garg, MBBS, MSC,*§ David J. Cohen, MD, MSC,‡ Thomas Gaziano, MD, MSC,†
Laura Mauri, MD, MSC*§
Boston, Massachusetts; and Kansas City, Missouri
Objectives We sought to define what incremental risk of very late stent thrombosis (VLST) in drug-eluting stents (DES)
would outweigh the restenosis benefit.
Background Although there are robust data on the restenosis benefit of DES versus bare-metal stents (BMS), the incremental
risk of stent thrombosis, a rare but serious complication of percutaneous coronary intervention (PCI), is not
known with certainty.
Methods We developed a decision analytic Markov model comparing DES versus BMS strategies for a contemporary PCI
population. Procedure-related morbidity and mortality data from published reports were used to derive the
model probabilities. Over a range of incremental risk and duration of risk of VLST, we identified the net benefit
of DES versus BMS in terms of quality-adjusted life expectancy (QALE).
Results Under an assumption of equal stent thrombosis rates beyond 1 year, the DES strategy was superior to BMS in
terms of QALE (16.262 vs. 16.248 quality-adjusted life years [QALYs], difference  0.014). Under the alternative
assumption of an incremental risk difference of 0.13%/year, the net benefit was substantially reduced (differ-
ence  0.001 QALYs). The threshold excess risk of very late DES thrombosis compared with BMS, above which
BMS would be the preferred strategy, was 0.14%/year (over 4 years of follow-up). This threshold increased as
the population risk of restenosis increased and decreased as the vulnerable time window lengthened.
Conclusions A small absolute increase in DES thrombosis compared with BMS after 1 year (0.14%/year) would result in
BMS being the preferred strategy for the overall PCI population. Larger clinical trials with longer follow-up are
needed to estimate the risk of late stent thrombosis with greater certainty for existing and new DES. (J Am
Coll Cardiol 2008;51:1844–53) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.042a
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ireatment with percutaneous coronary intervention (PCI)
ims to provide sustained relief of coronary ischemia and
ngina. As an invasive strategy, it is associated with risks
uring and after the procedure. Periprocedural risks have
ecreased over time despite treatment of patients with more
omplex lesions (1). Within the first year of treatment,
ecurrent angina related to progressive renarrowing of the
reated arterial segment is predictable according to stent and
atient characteristics and might be prevented by elution of
edications from stents that suppress neointimal hyperpla-
ia. Thrombotic occlusion or stent thrombosis, however, is
rom the *Divisions of Cardiology and Clinical Biometrics and the †Division of
ardiology and Social Medicine, Brigham and Women’s Hospital, Harvard Medical
chool, Boston, Massachusetts; ‡Saint Luke’s Mid-America Heart Institute, Univer-
ity of Missouri–Kansas City, Kansas City, Missouri; and the §Harvard Clinical
esearch Institute, Boston, Massachusetts. Dr. Cohen has received research grant
upport from Cordis and Boston Scientific.b
Manuscript received September 18, 2007; revised manuscript received November
9, 2007, accepted January 6, 2008.rare but potentially fatal event that is less well character-
zed in terms of absolute and relative risks over time.
Despite the dramatic early efficacy of drug-eluting stents
DES) in reducing restenosis compared with bare-metal
tents (BMS) (2,3), there is concern that DES might lead to
igher rates of stent thrombosis—particularly beyond the
rst year after implantation (4). Although restenosis might
e associated with unstable angina and myocardial infarc-
ion (MI), its more common clinical manifestation is pro-
See page 1854
ressive angina (5). In contrast, stent thrombosis is usually
ssociated with ST-segment elevation MI and high mortal-
ty (6–9). Therefore, the consequences of restenosis and
hrombosis are difficult to compare. Furthermore, the in-
remental risk of late stent thrombosis in DES versus BMS
s not known with certainty; randomized trials to date have
een limited in their power to detect rare and late events
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ion and ascertainment bias (11). Even large meta-analyses
f broader randomized trial data have yet to resolve this
ncertainty and suggest that DES might be associated with
2- to 4-fold increased risk of very late thrombotic events
12).
Decision analysis is a tool for combining data from multiple
ources that can be useful in guiding complex medical deci-
ions, particularly when there is uncertainty regarding 1 or
ore key parameters. The precise differences in the risk of
tent thrombosis between DES and BMS are not known but
ave important implications for patient care. Understanding
he trade-off that might exist between restenosis prevention
nd avoidance of stent thrombosis would provide the context
or the extended follow-up of existing DES as well as guidance
egarding reasonable margins of safety for the development of
ew stents. Therefore, we sought to define what incremental
isk of stent thrombosis in DES would outweigh the benefits
f restenosis prevention.
ethods
e developed a decision analytic Markov model comparing
common strategies in PCI: stenting with DES versus
tenting with BMS. A Markov model simulates transitions
etween distinct health states that would occur over a
ifetime in a cohort of patients undergoing a selected
reatment strategy (13). Procedure-related morbidity and
ortality data derived from published reports were used to
erive the model probabilities, and the outcome from each
trategy was quantified in terms of quality-adjusted life years
QALYs). On the basis of this model, we sought to identify
he threshold risk of very late stent thrombosis (VLST)
bove which the strategy of DES use was no longer
uperior.
atient population. Our model was designed to be applied
o a typical U.S. patient requiring and undergoing PCI
menable to either BMS or DES. Where possible, the char-
cteristics of the patient population were chosen to match
hose of contemporary population-based PCI registries.
ecision model structure. A decision analytical Markov
odel was constructed covering the possible outcomes for a
atient over a lifetime after the index procedure. The first
ear of the model was divided into 3 distinct periods: 0 to 30
ays after the index procedure, 30 days to 6 months, and 6
onths to 1 year. After the first year, subsequent health
tates in the Markov model were based on a cycle length of
year. These periods were chosen to correspond to the
nown biology of restenosis and thrombosis after stent
mplantation. Stent thrombosis was considered “early” dur-
ng the first 30 days after implantation, “late” between 1
onth and 1 year, and “very late” beyond 1 year, for consis-
ency with recently developed terminology by the Academic
esearch Consortium (ARC) (14).
Figure 1A depicts the initial treatment strategy (DES vs.MS) and the immediate and 30-day outcomes of the chosen Mrocedure in the form of a decision
ree. During the initial 30-day
ollow-up period, patients could
xperience noncardiac death or
ardiac death unrelated to stent
hrombosis. In the absence of
hese events, patients were at risk
or stent thrombosis. All patients
ith stent thrombosis were as-
umed to either die or suffer a
onfatal MI (6). Survivors of
tent thrombosis were assumed
o undergo target vessel revascu-
arization (TVR) with a variety
f possible strategies, including
onventional balloon angioplasty
percutaneous transluminal coro-
ary angioplasty [PTCA]), stent-
ng with DES or BMS, or coro-
ary artery bypass graft surgery
CABG). Patients were not considered at risk for restenosis
ithin the first month, consistent with known biology.
During the ensuing 11 months, survivors of the first 30
ays after the index procedure were at risk of clinically
ignificant restenosis and stent thrombosis in addition to
ackground risks of noncardiac and cardiac mortality. The
asic structures of the sub-trees for the periods from 1 to 6
onths and from 6 to 12 months were identical (Fig. 1B),
ut with differing probability estimates. Patients who expe-
ienced late stent thrombosis could either die or suffer a
onfatal MI. For simplicity, all patients with clinical reste-
osis were assumed to undergo TVR and were at risk for
onfatal MI (both at the time of presentation and as
omplication of the procedure) as well as procedure-related
ortality. The options for TVR for clinical restenosis
ncluded PTCA and repeat stenting with either DES or
MS in both arms of the model with subsequent risk of
rocedure-related mortality and CABG. Because brachy-
herapy is no longer generally available in the U.S., it was
ot included as a treatment strategy in our model. Nonfatal
I in the absence of restenosis and stent thrombosis was
lso modeled. Patients who survived months 1 to 6 (with or
ithout restenosis) were at risk for the same events during
onths 6 to 12 (with different probabilities). We assumed
hat patients could experience up to a maximum of 3
pisodes of stent thrombosis (1/distinct model period) and 2
pisodes of clinical restenosis within the first year after the
ndex procedure.
The Markov model that describes potential health states and
ransitions beyond the first year after PCI is depicted in Figure
C. The specific health states that we considered included: 1)
urvivors without TVR; 2) survivors after TVR; 3) post-
ABG survivors; 4) survivors beyond the interval of risk for
LST; and 5) death. Each of the first 4 health states was
urther stratified according to the presence or absence of prior
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
PTCA  percutaneous
transluminal coronary
angioplasty
QALE  quality-adjusted
life expectancy
QALY  quality-adjusted
life year
TVR  target vessel
revascularization
VLST  very late stent
thrombosisI (not shown in the figure). Because most studies indicate
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bserved at 1 year is maintained over the next 3 to 4 years (15),
e assumed that clinically significant restenosis and TVR
ould occur only during the first year after the index proce-
Figure 1 Schematic of the Markov Model
(A) Decision tree representing the outcomes in the first 30 days after the index
procedure. (B) Decision tree representing the outcomes in the period 30 days to 6
months. The tree for the period 6 months to 1 year is similar. (C) Bubble diagram
shows the initial therapeutic decision between drug-eluting stent (DES) and bare-
metal stent (BMS) followed by the first year of life after the index procedure. The
Markov health states are represented in the ovals with arrows indicating move-
ment between the states from 1 year to next. Each of the health states were fur-
ther subdivided on the basis of prior myocardial infarction but is not shown for
simplicity and brevity. CABG  coronary artery bypass graft surgery; MI  myocar-
dial infarction; ST  stent thrombosis; TVR  target vessel revascularization.ure. During each cycle, patients in the first 2 health states fere at risk for VLST. Patients in each of the health states
ere at risk for additional cardiac events, including cardiac
eath (unrelated to stent thrombosis) as well as noncardiac
eath.
ata sources for decision model. Probabilities of proce-
ural success and complications after stenting were derived
rom a review of the published medical reports as well as
npublished data presented at scientific meetings. Details of
hese data sources are provided in the Online Appendix and
re summarized in Tables 1 to 3 (16–38). To accurately
eflect the contemporary real-world clinical experience with
oronary stenting, whenever possible, absolute event rates
ere derived from registry data that describe the “real-
orld” outcomes of nonemergent PCI in the U.S. popula-
ion, whereas randomized controlled trial data were used
referentially to obtain unbiased estimates of the relative
isks of specific outcomes between the DES and BMS
trategies and also as a source of absolute event rates where
egistry data were lacking. Estimates of risk for the 2
pproved DES (Cypher, Cordis Corp., Miami Lakes, Flor-
da, and TAXUS, Boston Scientific, Natick, Massachusetts)
nd all BMS were pooled. Pooled estimates across publica-
ions were calculated with inverse variance weighting.
tent thrombosis estimates. We assumed the identical
robability of early (30 days) and late stent thrombosis (30
ays to 1 year) for the 2 treatments, because there is no
vidence of difference in stent thrombosis rates at 30 days or
t 1 year in the randomized trials (10,15), and examined a
ange of risks of VLST (1 year) from the published
eports. For our primary analysis, we used values derived
rom a pooled analysis of the long-term (4 year) results of
he pivotal randomized controlled trials comparing DES
ith BMS with the ARC definitions (10). These studies did
ot demonstrate a statistically significant excess of definite
r probable VLST in DES over BMS, but the absolute
ifference over 2 to 4 years was 0.39% (DES 0.90% vs. BMS
.51%). Therefore, we evaluated 2 possible baseline sets of
ssumptions: 1) that the incidence of VLST was identical
or the 2 stent types (0.22% annually; Scenario A); or 2) that
he incremental risk of VLST for DES versus BMS was
.13%/year for DES (i.e., absolute risk of 0.30%/year for
ES vs. 0.17% for BMS; Scenario B). In either scenario,
he risk of VLST was assumed to persist through 4 years
fter initial treatment. These assumptions were varied ex-
ensively in sensitivity analyses. Further details and expla-
ation of the data sources are provided in the Online
ppendix.
uality-of-life adjustments. The outcomes of each treat-
ent strategy were quantified in terms of quality-adjusted
ife years (QALYs) over a patient’s lifetime, as noted
reviously. In this context, 1 year of life without angina,
evascularization, or hospital stay was assumed to be a year
f perfect health and was assigned a value of 1.0 QALY.
ata on utilities and QALYs for patients with coronary
rtery disease undergoing revascularization were obtained
rom a previous study (Stent-PAMI [Stent-Primary An-
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OL health status instrument was used to assess utilities
or 771 PCI patients during the year after initial treat-
ent (35,36,39). In that study, the mean quality-adjusted
ife expectancies (QALEs) for patients with and without
epeat revascularization during the first year of follow-up
ere 0.79 and 0.85, respectively (p  0.001). The
ifference between these values was assumed to represent
he mean disutility associated with revascularization,
hich was applied only during the year in which the
evascularization actually occurred. Studies have previ-
aseline Probability Estimates
Table 1 Baseline Probability Estimates
Variable Estimate
Cardiac mortality (non-ST)
0 to 30 days 0.326% Lemo
30 days to 6 months 0.52% Lemo
6 months to 1 yr 0.38% Lemo
Beyond 1 yr (/yr) 1.5% Win e
Noncardiac mortality
0 to 30 days 0.081% U.S. L
30 days to 6 months 0.405% U.S. L
6 months to 1 yr 0.486% U.S. L
Nonfatal MI (annual; excluding ST and restenosis-related) 1.3% Cutlip
Probability of ST
0 to 30 days 0.65% Cutlip
Lem
30 days to 6 months 0.136% Iakovo
Da
6 months to 1 yr 0.164% Iakovo
Da
Annual VLST risk (2–4 yrs) – Scenario A 0.22% Poole
Annual VLST risk (2–4 yrs) – Scenario B 0.30%/0.17% Point
ST mortality 20% Cutlip
On
Probability of TVR, (DES/BMS)
30 days to 6 months 2.4%/6.7%* Moses
Urb
6 months to 1 yr 2.5%/7.0%* Moses
Urb
Initial management of restenosis Urban
PTCA 40%
DES 50%
CABG 10%
Initial management of ST Hwan
PTCA 66%
BMS 4%
DES 22%
CABG 8%
Procedural/in hospital death Willia
PTCA 0.12%
BMS 0.12%
DES 0.12%
CABG 2.1%
Bare-metal stent (BMS) clinical target vessel revascularization (TVR) estimates derived from dru
linical TVR with DES compared with BMS.
CABG  coronary artery bypass graft surgery; Mass-DAC  Massachusetts Data Analysis Cen
hrombosis; STS  Society of Thoracic Surgeons; VLST  very late stent thrombosis.usly demonstrated that, by 12 months, there is virtually so quality-of-life difference between patients with and
ithout repeat revascularization (35).
We assumed that MI (regardless of the underlying
ause) would decrease both long-term survival and quality
f life beyond the first year of follow-up but that
evascularization would not, because previous studies
ave not shown a consistent association between coronary
estenosis and long-term mortality (40). We also adjusted
uality-of-life measurements to account for the short-
erm morbidity of nonfatal MI and CABG by basing
hese adjustments on the estimated duration of hospital
Source
, 2004 (16); Urban et al., 2006 (17); Williams et al., 2006 (18)
, 2004 (16); Urban et al., 2006 (17); Williams et al., 2006 (18)
, 2004 (16); Urban et al., 2006 (17); Williams et al., 2006 (18)
007 (19)
les 2003 (20)
les 2003 (20)
les 2003 (20)
2004 (21); Urban et al., 2006 (17); Williams et al., 2006 (18)
2001 (6); Kuchulakanti et al., 2006 (8); Ong et al., 2005 (9);
al., 2004 (16); Urban et al., 2006 (17); Williams et al., 2006 (18)
l., 2005 (7); Kuchulakanti et al., 2006 (8); Mauri et al., 2007 (10);
et al., 2007 (11); Urban et al., 2006 (17)
l., 2005 (7); Kuchulakanti et al., 2006 (8); Mauri et al., 2007 (10);
et al., 2007 (11); Urban et al., 2006 (17)
ate (DES & BMS), Mauri et al., 2007 (10)
te (DES & BMS), Mauri et al., 2007 (10)
2001 (6); Iakovou et al., 2005 (7); Kuchulakanti et al., 2006 (8);
, 2005 (9); Ong et al., 2005 (22)
, 2003 (2); Stone et al., 2004 (3); Stone et al., 2004 (23); Lemos et al., 2004 (16);
al., 2006 (17); Williams et al., 2006 (18); Saia et al., 2006 (24)
, 2003 (2); Stone et al., 2004 (3); Stone et al., 2004 (23); Lemos et al., 2004 (16);
al., 2006 (17); Williams et al., 2006 (18); Saia et al., 2006 (24)
2006 (17); expert opinion
, 2006 (25)
al., 2006 (18); Win et al., 2007 (19); Mass-DAC 2006 (26); STS Data 2006 (27)
g stent (DES) estimate and based on randomized data showing a 65% relative risk reduction in
 myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty; ST  stents et al.
s et al.
s et al.
t al., 2
ife tab
ife tab
ife tab
et al.,
et al.,
os et
u et a
emen
u et a
emen
d estim
estima
et al.,
g et al.
et al.
an et
et al.
an et
et al.,
g et al.
ms et
g-elutin
ter; MItay and recuperation from such an event (37,38). Details
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rovided in the Online Appendix.
nalytic method and sensitivity analysis. For each of the
strategies we calculated QALE and considered the strat-
gy associated with a higher value to be preferred. Because
ur model was based on a number of assumptions, we
erformed 1-way and multi-way deterministic sensitivity
nalyses to examine whether and how plausible variations in
hese assumptions and risks (in particular, the probability of
LST) would alter our findings. We also performed prob-
bilistic sensitivity analysis in which we allowed each of the
ey variables of the model to vary simultaneously according
o its underlying distribution; in general, these distributions
ere based on the log-normal or beta distribution and were
erived by iterative fitting on the basis of published data
where available) or plausible ranges where not published
see Online Appendix). The Markov model was designed
nd all analyses were performed with TreeAge Pro Suite
007 software package (TreeAge Software, Inc., Williams-
own, Massachusetts).
esults
ALE of DES and BMS strategies. The model-
redicted QALE for a typical 62-year-old patient under-
oing PCI was 16.262 years after DES treatment and
6.248 years after BMS treatment under the assumption
f no difference in VLST risk (Scenario A). Thus, for a
rototypical PCI patient, stenting with DES would be
referred over BMS with a small net gain in QALE.
owever, the QALE for the 2 treatments were virtually
dentical under the assumption of 0.13% difference in
LST risk (Scenario B; DES 16.254 vs. BMS 16.253
ALYs). The predicted numbers of events/10,000 pa-
ients according to treatment strategy are shown in Table
Baseline Relative Risks
Table 2 Baseline Relative Risks
Variable RR
TVR RR reduction with DES 0.65 Mose
ST RR between DES and BMS (to 1 yr) 1.00 Maur
ST RR increase with prior TVR 1.20 Maur
TVR RR increase with prior TVR 1.10 Alfon
Ka
Cardiac mortality RR increase with prior MI 1.30 Cole
Va
RR  relative risk; other abbreviations as in Table 1.
Quality of Life Adjustments
Table 3 Quality of Life Adjustments
Variable
Year of life with CAD and no revascularization 0.
Year of life with CAD and revascularization 0.
Net disutility of revascularization
Nonfatal myocardial infarction relative utility weight
CABG 1CABG  coronary artery bypass graft surgery; CAD  coronary artery disease. Under the assumption of 0.13%/year difference in
LST rates between DES and BMS (Scenario B), there
ere 37 additional episodes of VLST resulting in 7
eaths in DES compared with 890 additional episodes of
VR in BMS. At 4 years, there were 6 additional deaths
n DES, largely due to stent thrombosis.
LST risk threshold for drug-eluting stenting strategy.
igure 2 demonstrates the effect of varying risks of VLST
n the gain in QALE with DES versus BMS. As the risk of
LST increased, the gain in QALE with DES implanta-
ion decreased. When the absolute excess risk of VLST in
ES exceeded 0.14%/year (over 4 years of follow-up), BMS
mplantation became the preferred treatment strategy.
iven that the duration of the risk of stent thrombosis is
lso currently uncertain, we explored this threshold risk as a
unction of time (Fig. 3). The annual excess risk for VLST
n DES that would be acceptable decreased as the
uration of the risk period was increased, as expected. For
xample, if the excess risk of VLST were to persist for 5
ears after PCI, the maximum excess risk above which
MS would be the preferred strategy was 0.11%/year; if
he risk were to persist for 10 years, the threshold would
all to 0.05%/year.
ensitivity analyses. Figure 4 shows the impact of other
ey model parameters on the estimated threshold of excess
ate stent thrombosis risk above which DES would no
onger be preferred. The most influential parameters were
he stent thrombosis case fatality rate, the magnitude of
ifferences in clinical restenosis and VLST rates, and the net
isutility associated with clinical restenosis. The threshold
isk of late stent thrombosis was insensitive to plausible
ariations in most other model parameters.
In 2-way sensitivity analyses, we explored the effect of
arying the baseline BMS target vessel revascularization
Source
l., 2003 (2); Stone et al., 2004 (3); Stone et al., 2004 (23)
, 2007 (10); Moreno et al., 2005 (28)
, 2007 (10)
l., 2005 (29); Alfonso et al., 2006 (30);
et al., 2005 (31)
2003 (32); Lloyd-Jones et al., 2003 (33);
et al., 2004 (34)
te Source
L yrs Cohen et al., 2001 (35); Bakhai et al., 2006 (36)
L yrs Cohen et al., 2001 (35); Bakhai et al., 2006 (36)
Cohen et al., 2001 (35); Bakhai et al., 2006 (36)
Tsevat et al., 1993 (37)
days Cohen et al., 1994 (38)s et a
i et al.
i et al.
so et a
strati
et al.,
ccaroEstima
85 QA
79 QA
0.06
0.88
4 QAL; QAL  quality-adjusted life.
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he baseline risk of TVR increased, the annual probability
f VLST above which DES would no longer be the
referred revascularization strategy increased (Fig. 5).
or example, if the BMS TVR rate was 20% (as com-
ared with the average population rate of 14%), then the
aximum tolerable risk of VLST in DES increased to
.20%/year over 4 years of follow-up.
Because DES might vary in the degree of suppression of
eointimal hyperplasia and restenosis, we performed a
ensitivity analysis to explore the effect of varying the
elative risk reduction in TVR rate with DES as compared
Figure 2 Threshold Analysis of the Risk of VLST in DES
This graph demonstrates the predicted difference in quality-adjusted life
expectancy (QALE) between drug-eluting stents (DES) and bare-metal stents
(BMS) over a range of excess risk for very late stent thrombosis (VLST) with
DES. At an annual risk of 0.14%/year (over 4 years), the predicted QALE was
equal for the 2 strategies, and above this level of risk BMS was the optimal
treatment strategy.
odel Predicted Number of Events/10,000 Patients
Table 4 Model Predicted Number of Events/10,000 Patients
Scenario A*
DES BMS
VLST risk (%/yr, 2–4 yrs) 0.22 0.22
Total death 1,013 1,016
Noncardiac death 419 419
Cardiac death (non-ST) 562 565
ST death 32 32
Nonfatal MI 720 763
MI due to restenosis 24 68
MI due to ST 125 125
ST events
1 yr 94 94
2–4 yrs (VLST) 63 63
ST-related death
1 yr 19 19
2–4 yrs (VLST) 13 13
TVR 479 1,367
QALYs 16.262 16.248
umber of events are over a 4-yr period unless stated otherwise. *Scenario A incidence of VLST
bsolute risk of 0.30%/yr for DES vs. 0.17% for BMS).
Abbreviations as in Tables 1 and 3.ith BMS. Not surprisingly, we found that as the relative
fficacy of a DES decreased, the threshold incremental
LST risk decreased (Fig. 6). For example, if the relative
isk reduction in TVR with DES decreased to 50% (com-
ared with our baseline estimate of 65%), the maximum
olerable rate of excess VLST decreased to 0.11%/year over
years of follow-up.
Because individual patients might differ in their will-
ngness to tolerate recurrent anginal symptoms as well as
he inconvenience and discomfort associated with addi-
ional revascularization procedures, we performed a
-way sensitivity analysis to explore the impact of varia-
ions in the disutility associated with restenosis on the
Figure 3 Threshold Risk of VLST in DES
as a Function of Risk Duration
As the theoretical risk period for stent thrombosis was extended, the annual
incremental risk of VLST in DES over BMS that preserved DES benefit
decreased. Abbreviations as in Figure 2.
Scenario B†
ES-BMS DES BMS DES-BMS
0 0.30 0.17 0.13
3 1,017 1,011 6
0 420 419 1
3 561 563 2
0 36 29 7
43 735 749 14
44 24 68 44
0 143 113 30
0 94 94 0
0 85 48 37
0 19 19 0
0 17 10 7
888 480 1,370 890
0.014 16.254 16.253 0.001
l for DES and BMS; †Scenario B incremental risk of VLST for DES over BMS was 0.13%/yr (i.e.,D



identica
o
a
e
u
v
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ssociated with restenosis decreased, the maximum tol-
rable DES thrombosis risk decreased. However, even
Figure 4 1-Way Sensitivity Analyses
This graph demonstrates the relationship between plausible variations in key mod
which DES would be preferred over BMS. The model was most sensitive to variatio
thrombosis of DES versus BMS, and the disutility associated with repeat revascul
threshold value of the VLST in DES and vice versa. CAD  coronary artery dise
Figures 1 and 2.
Figure 5 Threshold Risk of VLST in DES as a Function of
the Baseline BMS Population Risk of Restenosis
Under the base case assumptions of annual BMS TVR rate of 14%, the incre-
mental risk of VLST in DES over 3 years was 0.14%/year, over which the pre-
ferred strategy would be BMS. As the population risk of restenosis (and TVR)
increases over the expected rate of 14%, as observed in diabetic patients,
small vessels, and long lesions, the annual incremental risk of VLST in DES
over BMS that preserves DES benefit increased. Abbreviations as in Figures 1
and 2.nder the extreme situation of a patient who assigned no
alue to avoidance of restenosis (i.e., disutility  0), a
mall excess risk of very late thrombosis with DES would
e acceptable (i.e., 0.08%/year), owing to the non-
meters and predicted maximum tolerable excess risk of VLST in DES, below
the stent thrombosis case fatality rate, the relative risks of TVR and late stent
n. *The higher range value of the estimate for this variable results in a smaller
ALY  quality-adjusted life years; RR  relative risk; other abbreviations as in
Figure 6 Threshold Risk of VLST in DES as a Function
of the RR Reduction in Clinical Restenosis With DES
Current DES reduce target vessel revascularization (TVR) by 65%. If the relative
risk (RR) reduction in TVR with DES was lower than 65%, then the annual incre-
mental risk of VLST in DES that preserved DES benefit over BMS was decreased.
Abbreviations as in Figures 1 and 2.el para
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ubsequent treatment.
Finally, we performed probabilistic sensitivity analyses
y simultaneously varying all of the parameters listed in
igure 4. Under Scenario A (equal VLST risk for DES
nd BMS), we found that the DES strategy was the
referred strategy over BMS in 91.1% of trial iterations
ith a mean life-expectancy of 16.30 QALYs in DES
95% confidence interval 14.74 to 17.72) and 16.29
ALY in BMS (95% confidence interval 14.73 to 17.71).
nder Scenario B (0.13%/year excess VLST with DES),
owever, the DES strategy was preferred in only 56% of
terations.
iscussion
ecisions regarding percutaneous treatment of obstructive
oronary disease have become increasingly challenging for
atients and physicians since the observation of delayed stent
hrombosis in DES. The main risk attributable to bare-metal
tenting was restenosis requiring repeat revascularization—a
isk that largely ended within 1 year after stenting (41,42).
eyond this period, events attributable to the stent were rare
21). In particular, in-stent thrombotic complications occurred
n 1% of patients, almost exclusively within the first month
fter BMS implantation. By limiting neointimal hyperplasia
ithin the stent, the current generation of DES have reduced
he occurrence of clinical restenosis by 50% to 70% (2,3).
owever, there is concern that DES might be associated with
ncreased risks of delayed stent thrombosis. In this study, we
ought to quantify the degree to which current uncertainty in
he rate of very late thrombotic complications after DES
mplantation would affect the choice of an optimal PCI
trategy. Because both the absolute risk and duration of risk of
tent thrombosis after DES implantation are uncertain, we
Figure 7 Two-Way Sensitivity Analysis on the
Disutility Associated With Revascularization
This graph demonstrates the impact of the disutility associated with repeat
revascularization on the predicted maximum tolerable excess risk of VLST.
Abbreviations as in Figures 1 and 2.sed the techniques of decision analysis to define what thresh- ald of incremental risk with DES would outweigh the benefits
f reduced restenosis in clinical practice.
We found, on the basis of the best data currently available,
hat the DES strategy was preferred for a prototypical PCI
atient under the assumption of no difference in the rates of
LST (Scenario A). Although the benefit was small in
bsolute terms (0.014 QALYs), this gain is plausible given the
ime-limited nature of the restenosis process and the absence of
ong-term mortality benefit associated with restenosis avoid-
nce in most studies. This finding was confirmed to be robust
ith probabilistic sensitivity analysis, which allows one to
onsider a range of plausible probabilities rather than relying on
xed estimates alone. Nonetheless, we found that our results
ere highly sensitive to the absolute risk and duration of risk
or VLST, leading to uncertainty in the optimal decision over
range of risk that is plausible on the basis of current data. In
articular, for a prototypical patient, we found that even a small
xcess risk of VLST (0.14%/year over 4 years) would be
ufficient to negate any advantage of DES over BMS in terms
f QALE. Furthermore, if the at-risk period extended beyond
years, the incremental annual risk that could be tolerated was
ven smaller.
Whether the true risk of very late thrombosis with
xisting DES exceeds this risk is uncertain at present.
estenosis risks can be predicted with reasonable precision
n overall populations and according to well-understood
atient and lesion-based factors, because restenosis was a
requent occurrence over the past decade of practice. In
ontrast, stent thrombosis risks have only recently been
tudied with similar rigor. Although pooled analyses of
andomized trials of the 2 approved DES platforms to 4
ears of follow-up have not shown significant differences in
isk of thrombosis between drug-eluting and bare-metal
tents, the confidence intervals of these estimates are wide,
uggesting that up to a 1.4% absolute risk difference at 4
ears cannot be excluded (10). A larger network meta-
nalysis suggested that up to 4-fold increase in late hazard
or DES cannot be excluded (12). Currently, the best data
egarding VLST rates are from the pooled analysis of the
ivotal randomized trials of DES versus BMS (10,12,15). In
hese studies, the individual point estimates range of excess
isk range from 0.13% to 0.18%/year, depending on the
tudy and definition used (Fig. 8). Thus, the available data
o not provide a definitive answer regarding the preferred
tent strategy at the present time.
One should consider our results in the context of our
tudy design. Ideally, one would base the choice between
ES and BMS on large, long-term, randomized trials
onducted in a population that directly reflects the general
opulation. As in any decision analysis, we were limited by
he available data. To derive results applicable to the “real
orld” we chose to populate our decision analytic model
ith absolute risks derived from observational studies and
elative risks derived from randomized trials. This approach
llowed us to derive unbiased estimates of relative risk while
pplying these to the absolute risks seen in the general
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atients who would be eligible for randomized trials. Fur-
hermore, we addressed the inherent uncertainty in the
eported data by conducting sensitivity analyses (including
robabilistic sensitivity analysis) to determine the robustness
f our results.
In addition, we assumed a constant risk of stent throm-
osis beyond the first year (11). If the stent thrombosis risk
as a declining function rather than constant, then the
LST risk threshold would be somewhat higher in the
nitial years. We did not explicitly model the effects of
lopidogrel in this study, because of the conflicting data on
he efficacy of clopidogrel in decreasing the risk of VLST. It
s likely that the impact of extended dual antiplatelet
herapy, as seen in large trials of patients with acute
oronary syndromes, is predominantly mediated by preven-
ion of MI outside the stent territory, because the absolute
isk of progression of other atherosclerotic disease after
reatment is greater than the risk of stent thrombosis.
astly, we specifically chose not to include cost in our
odel, because the primary question we intended to answer
as a purely clinical one: what excess risk of late stent
hrombosis would be acceptable for a typical patient under-
oing PCI with stents to suppress restenosis?
mplications for clinical trials and new DES evaluation. Our
bservations suggest that it is clinically relevant to deter-
ine relatively small differences in risk of stent thrombosis.
o date, the available randomized trials, even when pooled,
ave been underpowered to detect such differences. For
xample, for a randomized noninferiority comparison to
Figure 8 Comparison of the Incremental Risk of VLST in DES in
Recently Published Studies With the Threshold Risk
The difference in observed yearly rates of VLST for sirolimus-eluting stents
(SES) and paclitaxel-eluting stents (PES), versus BMS, are shown as point esti-
mates taken from the recent pooled analyses (confidence intervals not shown)
(10,12). The DES versus BMS differences fall just below the VLST threshold
we identified (0.14%/year), signifying preserved overall benefit of DES versus
BMS; however, a small absolute increase in DES VLST would exceed the
threshold above which no net benefit would exist for DES over BMS. Abbrevia-
tions as in Figures 1 and 2.etect an absolute difference in VLST rates of 0.5% orore, a sample size of 10,000 patients would be required.
urthermore, the duration of risk is an important determi-
ant of net clinical benefit. Our analysis provides the
ontext of what upper limit of thrombosis rate can be
olerated once follow-up data to 5 years and beyond become
vailable.
Clearly, the ideal stent would avoid both restenosis and
tent thrombosis. Our model suggests that, despite a
mall increase in the risk of stent thrombosis, DES might
till provide a net clinical benefit to patients if the
xpected risk of restenosis with BMS is nontrivial and the
estenosis reduction is profound. However, new stent
latforms that differ in mechanism, drug, or polymer
rom current designs might vary in the degree of sup-
ression of neointimal hyperplasia and separately in the
isk of stent thrombosis. Our analysis suggests that, as the
elative risk reduction of restenosis decreases, the toler-
ble excess stent thrombosis risk must also diminish to
reserve the benefit of a DES strategy. That is, a DES
hat is less effective at preventing restenosis must be
equired to be very similar to or better than BMS in terms
f avoidance of thrombosis for a net advantage to exist.
onclusions
n the basis of a decision analytic model incorporating the
est data currently available, we found that even a small
1%) incremental risk of thrombosis in DES might be
ufficient to outweigh the benefit of restenosis prevention
nd favor BMS use for the overall PCI population. To
dentify whether risks of restenosis can be safely reduced,
valuation of existing and new DES must be adequately
owered and have sufficient length of follow-up in order to
etermine both the relative and absolute risks of stent
hrombosis with greater certainty.
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